Reports to: Director, Accounting

Position Summary
Poseida is seeking an outstanding candidate to join our Accounting and Finance team.  The Associate Director of Financial Reporting leads and owns SEC reporting, technical accounting, equity administration and other key financial reporting items. This person will be a key member in the accounting department to implement new processes as a newly public company within the financial reporting function.

These may include but are not limited to:

  • SEC reporting- preparing SEC filings, including Form 10-K’s, 10-Q’s, as well as other required filings (8-k, S-8, proxy)
  • Preparing appropriate support for all filings and coordinating with external auditors
  • Accounting/disclosure guidance adoptions – responsible for monitoring and implementing
    new accounting guidance and disclosure rules from relevant authoritative bodies (SEC, FASB);
  • Update XBRL for financial statements to the appropriate US GAAP taxonomy
  • Technical accounting research and memos- responsible for all accounting research, memo preparation and supporting schedules for implementing new accounting guidance, evaluating potential transactions (collaborations, financing, etc.)
  • Equity administration – manage administration of stock award activity and related stock-based compensation financial reporting
  • Prepare journal entries for various items as they relate to stock-based compensation, guidance implementation and other various areas, as appropriate
  • Prepare and update process narratives for areas of ownership
  • General accounting support- ability to perform ad hoc projects as needed to support the accounting department

Requirements, Knowledge, Skills and Abilities

  • Bachelor’s degree in accounting required with a minimum of 7 plus years of public accounting experience with SEC clients or 7 years of experience in a financial reporting role for a publicly traded company (a combination of experience and education may be considered)
  • Strong understanding of US GAAP and ability to independently research
  • Strong understanding of SOX/internal controls
  • Demonstrated problem-solving and critical thinking skills
  • Ability to meet monthly and quarterly reporting deadlines
  • Active Disclosure experience required
  • Great Plain and Equity Edge experience strongly preferred
  • Demonstrated ability to work effectively in a dynamic, complex and fast-paced team environment

Who We Are and What We Do

Poseida Therapeutics is a San Diego-based clinical-stage biopharmaceutical company dedicated to utilizing our proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. We have discovered and are developing a broad portfolio of cell and gene product candidates in a variety of indications based on our core proprietary platforms, including our non-viral piggyBac® DNA Modification System, Cas-CLOVER™ site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies.

We are continually innovating and growing as we advance our clinical trial program. We are passionate about the impact that we will make with our research in liquid and solid tumor cancers and gene therapies for rare diseases. Our wholly-owned portfolio of product candidates are designed to overcome the primary limitations of current generation cell and gene therapeutics, and includes:

Autologous Programs

  • Our most advanced product candidate, P-BCMA-101, is an autologous CAR-T targeting BCMA that we are currently evaluating in an expanded Phase 1 clinical trial and a Phase 2 clinical trial for the treatment of patients with relapsed/refractory multiple myeloma.
  • We have initiated a Phase 1 clinical trial with patient dosing for our second autologous product candidate targeting PSMA, P-PSMA-101, for the treatment of patients with metastatic-castrate resistant prostate cancer.

Allogeneic Programs

  • P-BCMA-ALLO1 for patients with relapsed/refractory multiple myeloma, where we expect to file an investigational new drug (IND) application and initiation of a Phase 1 clinical trial in late 2020.
  • Additional candidates in preclinical development include P-MUC1C-ALLO1 for multiple solid tumors with an anticipated IND filing and initiation of a Phase 1 clinical trial in late 2021 as well as P-PSMA-ALLO1 for metastatic castrate-resistant prostate cancer with an anticipated IND filing and initiation of a Phase 1 clinical trial in late 2022.

DUAL CAR Allogeneic Programs

  • Designed to include two or more fully functional CAR molecules into a T cell, we have preclinical studies ongoing with DUAL CAR (CD19/CD20) in B cell malignancies and DUAL CAR (BCMA/CD19) in multiple myeloma where we anticipate filing INDs and initiating Phase 1 clinical trials in late 2021 and 2022. We also expect to initiate a trial in an undisclosed target in solid tumors in the future.

Gene Therapy Programs for Rare Diseases

  • Two liver-directed gene therapies combining our piggyBac® DNA Modification System with AAV/nanoparticle technology – P-OTC-101 for the in vivo treatment of Ornithine Transcarbamylase deficiency where we expect to file an IND and initiation of a Phase 1 clinical trial in late 2021 or early 2022. And a second candidate, P-MMUT-101, in Methylmalonic Acidemia, with an anticipated IND filing and initiation of a Phase 1 clinical trial in 2022.

Association of Bioscience Financial Officers


Interested candidates, please use this link to apply online

To see this and other open financial positions with our ABFO member companies,
please visit our ABFO website job posting page

To view this html email as a webpage in your browser, please use this link

You are receiving this notice because you have indicated interest in ABFO, are an ABFO Member Representative,
or have come to one of our meetings.
If you have questions or comments or wish to be removed from our distribution list, please contact the ABFO Membership Coordinator, Genie Hawkins at